Synairgen Share Discussion Threads

[waterloo01] 31/5/2020 13:41

From the Lancet




Most published studies so far have been retrospective or observational. Therefore, this prospective, randomised controlled design adds notable value to the growing evidence on treatments, eliminating a number of limitations inherent to retrospective studies. Additionally, despite the relatively small number of patients in the interferon beta-1b subgroup, significant differences in outcomes were demonstrated. Therefore, this study provides much needed data on a potential therapeutic regimen for SARS-CoV-2.

[sgn001] 31/5/2020 13:35

Thanks nobby. Much appreciated. This is a brilliant board when you use filter.

[waterloo01] 31/5/2020 13:29

If it works, which seems less in doubt with the release of papers showing it does reduce COVID viral load, if given early enough, it's delivery via nebuliser has loads of benefits to both patient and hospitals,with the possibility of early cases being treated at home (self administered) and a significant reduction in the numbers needing hospital interventions, and in those reduced recovery times, similar to Remdesvir the best current treatment.

As said, while I wouldn't bet the house on it, the shed seems appropriate.

[nobbygnome] 31/5/2020 13:21

>> Sgn001

The deal has been in the offing for a long time. However, Pharmaxis decided to do an extra trial presumably because of preliminary discussions; it actually escapes me what it was but I think it was related to the tox package (timbo?).

So a deal could come at any time but I wouldn't hold your breath because it has been in the process for so long. They do have good phase I data with some evidence of in vivo enzyme inhibition. In addition, fibrosis is a hot area in Pharma as it is a relatively high unmet need. For example IPF is one of the nastiest diseases of the lot yet no-one has heard of it. I am sure they will sign a lucrative deal but the timeframe is uncertain.

[sainvestor] 31/5/2020 13:14

I think the safety doubt is no longer in play. Home trials would not have started if they were. The question is how much of a difference does the treatment provide? Did they get to the Covid patients at hospital in time with the right dose? The home trials will surely benefit the people but again to what degree? We know the treatment works. Nothing new there. The risk and worry here is does Covid-19 react in a way the other viruses haven't as it is unlike previous viruses.If the answer is no then we're all going on holiday :-)

[spartan attack] 31/5/2020 12:50

never know. Might be a buyer just prior to the date, but also dump it day before too haha

[spartan attwat] 31/5/2020 12:49

For once we agree, both dogs of shares.see you back here in July☺

[waterloo01] 31/5/2020 12:47

Couple of excellent papers posted. All seem to point in the same direction that given early enough, treatment with INFA reduces viral load and speeds recovery.

"The data shown in Figure 1 reveal the statistically significant accelerated viral clearance from the upper respiratory tract in patients who received IFN-α2b treatment (20.4 days, p = 0.002). i.e., IFN treatment accelerated viral clearance by ~7 days."


"The 28-day overall mortality was significantly lower in the IFN then the control group (19% vs. 43.6% respectively, p= 0.015). Early administration significantly reduced mortality (OR=13.5; 95% CI: 1.5-118). Conclusion: Although did not change time to reach the clinical response, adding to the standard of care significantly increased discharge rate on day 14 and decreased 28-day mortality. Clinical Trial Registration ID #IRCT20100228003449N28"

[spartan attack] 31/5/2020 12:42

Im off to opti threads full time now anyway. And SBTX

Extreme bear once they announce last pocket book

[spartan attack] 31/5/2020 12:42

Well agree. Suits you more

[spartan attwat] 31/5/2020 12:42

Thanks for the tip bro

[spartan attwat] 31/5/2020 12:41

Nah my name is better than yours.

[spartan attack] 31/5/2020 12:41

hahaha

Keep buying. Definitely deserve a shed load of them

[spartan attwat] 31/5/2020 12:40

No I'm his twin. He got the looks but I got the brains. But I guess you all knew that anyway. He gave me the tip off to buy on friday.

[wetdream] 31/5/2020 12:40

Came across this post from earlier which may be worth including in the header...
;-)

———————

Thanks for that (post #8367)

I note that in that study they administered the drug SC as indicated for MS (not IV as used by Faron for ADS).


SC administration will deliver the drug to the blood capillary system (rather than the blood venous system) which will result in some unwanted distribution to adjacent tissues around the injection site prior to entering the main vascular system, so intuitively IV should be a better route of administration (compared to SC) for administration to the lungs (where the drug is required), so had the interferon beta been administered via the IV route the outcome may have been even better.

Given that inhaled administration should be better than IV which should be better than SC this is certainly encouraging for SNG001 in the COVID studies

————————-

[spartan attack] 31/5/2020 12:39

It happens a lot by weak minded posters. They copy great names and pretend that name is bullish

hahaha

[sgn001] 31/5/2020 12:38

Does anyone have a qucik reference to LOXL2 inhibitors where a licensing deal(s) by Pharmaxis is valued or are we a while away from that yet?

[spartan attwat] 31/5/2020 12:25

Superb news. Take it all back. Back up to 60p

[nobbygnome] 31/5/2020 12:06

And to remind everyone the Chinese paper endorsed by Eleanor Fish the Canadian expert in the field.

[sainvestor] 31/5/2020 12:05

Can't see this as anything but positive. It then depends on how the market reacts to such a treatment. You would hope it's a huge step forward to be able to treat people at home, especially such a vulnerable subset. Getting this trial fully recruited without the slowing down we saw in the hospital trials is very important.

[nobbygnome] 31/5/2020 11:50

I was just looking at the protocol again as I was prompted to by waterloo's post yesterday about the inclusion and exclusion criteria. It is important to note that patients need to have had a Covid 19 positive test in the last 24 hours so these have to be new albeit relatively ill patients with the infection. So the point is they can't have been in hospital for days whilst slowly deteriorating, which improves the chance of a positive result along the lines of the Chinese study.